Ownership history in Mayar Capital Ltd. Β· 20 quarters on record
This page tracks every 13F SEC filing in which Mayar Capital Ltd. reported a position in LABORATORY CRP OF AMER HLDGS (LH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Mayar Capital Ltd. underperformed the S&P 500 by β8.4% annually on this LH position. Timing score: 40% (6/15 decisions correct). Average cost basis: $206.30. Maximum drawdown during holding period: β34.4%.
β Significantly underperformed the S&P 500 by 8.4% ann.
19 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
6 of 15 add/trim decisions correct
Best entry: $168.62 (2022 Q3) Β· Worst: $260.48 (2025 Q2)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 10 trims. Bought during 3 of 8 down-price quarters. π Predominantly trimming β distribution phase.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 2.84% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size